Direkt zum Inhalt
Merck
Alle Fotos(2)

Key Documents

View All Documentation

SML0061

Sigma-Aldrich

SAHA

≥98% (HPLC), powder, HDAC inhibitor

Synonym(e):

N-hydroxy-N′-phenyl-octanediamide, Suberoylanilide hydroxamic acid, Vorinostat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

Empirische Formel (Hill-System):
C14H20N2O3
CAS-Nummer:
149647-78-9
Molekulargewicht:
264.32
MDL-Nummer:
MFCD00945317
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825127
NACRES:
NA.77

product name

SAHA, ≥98% (HPLC)

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white to tan

Löslichkeit

DMSO: ≥15 mg/mL

Versandbedingung

wet ice

Lagertemp.

−20°C

SMILES String

ONC(=O)CCCCCCC(=O)Nc1ccccc1

InChI

1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

InChIKey

WAEXFXRVDQXREF-UHFFFAOYSA-N

Angaben zum Gen

human ... HDAC1(3065) , HDAC2(3066) , HDAC3(8841) , HDAC6(10013)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

SAHA may be used to study gene regulation, transcription regulation and cell signaling.

Biochem./physiol. Wirkung

SAHA or Vorinostat facilitates the transcription of genes that result in apoptosis, differentiation and growth arrest. It has been observed to give beneficial results in lymphoma but not in solid tumors.
Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a potent, reversible pan-histone deacetylase (HDAC) inhibitor. It inhibits both class I and class II HDACs, altering gene transcription and inducing cell cycle arrest and/or apoptosis in a wide variety of transformed cells.

Leistungsmerkmale und Vorteile

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H341,H360

Gefahreneinstufungen

Muta. 2 - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

SBHA A cell-permeable bishydroxamic acid histone deacetylase (HDAC) inhibitor with anti-tumor properties.

Sigma-Aldrich

559418

SBHA

5-Aza-2′-Desoxycytidin ≥97%

Sigma-Aldrich

A3656

5-Aza-2′-Desoxycytidin

CI−994 ≥98% (HPLC), powder

Sigma-Aldrich

C0621

CI−994

RGFP966 ≥98% (HPLC)

Sigma-Aldrich

SML1652

RGFP966

Prostratin ≥98% (HPLC)

Sigma-Aldrich

P0077

Prostratin

Sarah W Gordon et al.
American journal of clinical oncology, 42(8), 649-654 (2019-07-16)
Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma. Patients received vorinostat (200
Robert W Robey et al.
Molecular pharmaceutics, 8(6), 2021-2031 (2011-09-09)
The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell
Gloria Manzotti et al.
Journal of experimental & clinical cancer research : CR, 38(1), 346-346 (2019-08-10)
RUNX2 is a Runt-related transcription factor required during embryogenesis for skeletal development and morphogenesis of other organs including thyroid and breast gland. Consistent evidence indicates that RUNX2 expression is aberrantly reactivated in cancer and supports tumor progression. The mechanisms leading
Sachith Mettananda et al.
Scientific reports, 9(1), 11649-11649 (2019-08-14)
β-Thalassaemia is one of the most common monogenic diseases with no effective cure in the majority of patients. Unbalanced production of α-globin in the presence of defective synthesis of β-globin is the primary mechanism for anaemia in β-thalassaemia. Clinical genetic
Weiwei Yu et al.
British journal of pharmacology, 174(20), 3608-3622 (2017-07-28)
Intrinsic and/or acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly occurs in patients with non-small-cell lung cancer (NSCLC). Here, we developed a combined therapy of histone deacetylase inhibition by a novel HDAC inhibitor, YF454A, with
Alle zugehörigen Dokumente anzeigen

Artikel

Autophagy in Cancer Promotes Therapeutic Resistance

We presents an article on Autophagy in Cancer Promotes Therapeutic Resistance

Histone Modification and Chromatin Remodeling | Epigenetics

Epigenetic modifications are thought to occur through two key interconnected processes—DNA methylation and the covalent modification of histones.

Verwandter Inhalt

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.